The American Association for the Study of Liver Diseases' (AASLD) 2009 and 2012 guidelines on the management of SBP recommends albumin infusion as an important component in managing patients with end-stage liver disease experiencing complications including grade 3/refractory ascites, acute kidney injury (AKI), and hepatorenal syndrome [17, 18]. Here, ALB is linked to hepatorenal syndrome.